Modified vitamin K-dependent polypeptides
AssigneeRegents of the University of Minnesota
InventorGary L Nelsestuen
Life of this patent
Estimating the term…
Abstract
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
Claims19
An isolated nucleic acid molecule, said nucleic acid molecule comprising a nucleic acid sequence encoding a mutant Factor VII (FVII) or mutant Factor VIIa (FVIIa) polypeptide, said mutant FVII or mutant FVIIa polypeptide comprising a modified γ-carboxyglutamic acid (GLA) domain that enhances membrane binding affinity of said mutant FVII or mutant FVIIa polypeptide relative to a wild type human Factor VII (hFVII) or wild type human Factor VIIa (hFVIIa) polypeptide, wherein said modified GLA domain comprises an amino acid sequence that differs from the amino acid sequence of the GLA domain of hFVII or hFVIIa polypeptide shown in SEQ ID NO:3 in 1 to 5 amino acid substitutions, wherein the proline residue at amino acid position 10 of SEQ ID NO:3 is substituted with a glutamine, aspartic acid or glutamic acid residue in the modified GLA domain, and wherein amino acid positions of the amino acid sequence of the modified GLA domain are numbered according to SEQ ID NO:3.
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a mutant FVII or mutant FVIIa polypeptide having clotting activity, said mutant FVII or FVIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said mutant FVII or mutant FVIIa polypeptide relative to a wild type hFVII or wild type hFVIIa polypeptide, wherein said modified GLA domain comprises an amino acid sequence that differs from the amino acid sequence of the GLA domain of wild type hFVII or wild type hFVIIa polypeptide shown in SEQ ID NO:3 in two amino acid substitutions, wherein a glutamine residue is substituted for the proline residue at amino acid position 10 of SEQ ID NO:3 and a glutamic residue is substituted for the lysine residue at position 32 of SEQ ID NO:3 in the modified GLA domain, and wherein amino acid positions of the amino acid sequence of the modified GLA domain are numbered according to SEQ ID NO:3.
Dependencies are inferred from the claim text.